SANGUINATE is an investigational bio-pharmaceutical product currently in clinical testing, designed to address the comorbidities of sickle cell disease and other disorders caused by anemia or hypoxia ischemia. It aims to transfer oxygen to oxygen-deprived cells and tissues, potentially treating conditions such as vaso-occlusive crisis, acute chest syndrome, leg ulcers, and stroke.
Developed by Prolong Pharmaceuticals, SANGUINATE has received Orphan Drug Designation from the U.S. FDA and is the only biological product in clinical development for the multiple comorbidities of sickle cell disease. Phase I studies have been completed, and Phase II trials are underway for various conditions, including delayed cerebral ischemia, vaso-occlusive crisis, leg ulcers, and delayed graft function following kidney transplantation.
Generated from the website